CONMED is aligning operations and resources within its core markets—minimally invasive, robotic, and laparoscopic surgery, smoke evacuation, and the surgical treatment of orthopedic soft tissue repair. The company is well-positioned for growth on the back of rising adoption of its high-margin, differentiated platforms like AirSeal, Buffalo Filter and BioBrace, with long-term prospects supported by rising robotic procedure volume and expanding penetration of Ambulatory Surgery Centers.
Cyborg Score Rationale
2025 revenue reached $1.37 billion with full-year net income of $47.06 million and EPS of $1.51, showing a sharp decline in profitability despite revenue growth. 2026 revenue guidance is essentially flat versus 2025, keeping margin pressure and earnings quality as key concerns.
Top Insights
CONMED announced its intention to exit gastroenterology product lines with the Gore VIABIL biliary stent distribution agreement concluding effective January 1, 2026, as part of portfolio optimization
2025 saw revenue growth to $1.37 billion but net income fell sharply to $47 million with 2026 guidance of $1.345-1.375 billion indicating flat growth
CFO Todd Garner departed effective March 15, 2026, remaining in advisory capacity through November 2026, with company initiating comprehensive search for replacement
For 2026, company guided to 50-100 basis points of gross-margin expansion and suspended dividend while authorizing $150 million share repurchase program
Named Competitors
Robotic-assisted surgical systems — da Vinci robotic surgery platform
Orthopedic devices and sports medicine — Comprehensive orthopedic and surgical solutions
Surgical equipment and devices — Broad portfolio of minimally invasive surgical tools
Recent Developments
(January 2026) CFO Todd Garner announced departure effective March 15, 2026
(January 2026) Q4 2025 earnings reported $373.2M revenue with $1.43 adjusted EPS; 2026 guidance of $1.345-1.375B revenue and $4.30-4.45 EPS
(December 2025) Announced strategic exit from gastroenterology product lines to focus on core markets
(November 2025) Company suspended quarterly dividend and extended $150M share repurchase program
Open the full interactive CONMED Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.